

<b>Policy Statement:</b>	<b>Peyronie's disease</b>
<b>Status:</b>	<b>Individual Prior Approval</b>

This is a benign penile condition characterized by curvature of the penile shaft secondary to the formation of fibrous tissue plaques within the tunica albuginea.

The West Essex Clinical Commissioning Group does not routinely fund treatment for Peyronie's disease. If there is no functional impairment that prevents intercourse then it is primarily considered to be cosmetic condition.

Funding for surgical or collagenase treatment will be assessed on an individual basis where the following criteria apply:

- The disease is in the stable phase  
AND
- Conservative measures have failed or not possible due to clinical reasons  
AND
- Severe disease that makes intercourse not possible

## References

1. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. *The Journal of urology*. 2006; 175(6):2115–2118
2. European Association of UrologistsK Hatzimouratidis (Chair), I. Eardley, F. Giuliano, I. Moncada, A. Salonia. *Guidelines on Penile Curvature* Eur Urol 2012 Sep;62(3):543-52.
3. NICE. Extracorporeal shockwave therapy for Peyronie's disease. 2003. Interventional procedure guidance 29. <https://www.nice.org.uk/guidance/ipg29/chapter/5-About-this-guidance>
4. London Medicines Evaluation Network. Collagenase Clostridium histolyticum ( Xiapex™) for Peyronie's disease – July 2015 <https://www.sps.nhs.uk/wp->

5. Gelbard M, Goldstein I, Hellstrom W.J.G et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronies disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013; 190(1):199-207.
6. Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. The journal of sexual medicine. 2015; 12(1):248–258.
7. Levine LA, Cuzin B, Stephen M et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease; a phase 3 open label study. The Journal of Sexual Medicine 2015; 12(1):248-258.
8. Bedfordshire and Hertfordshire Priorities Forum statement Number: 98 Subject: Peyronie's Disease September 2018
9. Yang, Kevin K. et al. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms. *Urology* Volume 94 , 143 - 147 <https://www.ncbi.nlm.nih.gov/pubmed/27211926>
10. Ziegelmann M, Viers B, McAlvany K et al. Resoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolytic Injection for Peyronie's Disease. Journal of Urology. 195(4):1051-1056
11. 8. Anaissie, J., Yafi, F. A., Traore, E. J., Sikka, S. C. and Hellstrom, W. J. G. (2017), Survey of patient and partner satisfaction following collagenase *Clostridium histolyticum* treatment for Peyronie's disease. *Andrology*, 5: 274–277. doi:10.1111/andr.12302
12. 9. Coyne KS, Currie BM, Thompson CL, and Smith TM. Responsiveness of the Peyronie's Disease Questionnaire (PDQ). J Sex Med 2015;12:1072–1079.
13. 10. Thoma, C. CCH injections reader effective by men with Peyronie's disease. *Nature Reviews Urology* 2015;12:654 <https://www.ncbi.nlm.nih.gov/pubmed/26526755>
14. 11. Abdel Raheem, A., Capece, M., Kalejaiye, O., Abdel-Raheem, T., Falcone, M., Johnson, M., Ralph, O. G., Garaffa, G., Christopher, A. N. and Ralph, D. J. (2017), Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. *BJU Int*, 120: 717–723. doi:10.1111/bju.13932
15. Carson, C. C., Sadeghi-Nejad, H., Tursi, J. P., Smith, T. M., Kaufman, G. J., Gilbert, K. and Honig, S. C. (2015), Analysis of the clinical safety of intralesional injection of collagenase *Clostridium histolyticum* (CCH) for adults with Peyronie's disease (PD). *BJU Int*, 116: 815–822. doi:10.1111/bju.13120
16. 13. Yafi, Faysal A. et al. Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum

for Peyronie's Disease The Journal of Sexual Medicine , Volume 13 , Issue 4 , 684 - 689

17. Yafi, Faysal A. et al Multi-institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium Histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease Urology , Volume 120 , 138 - 142
18. Surgical Treatment of Peyronie's Disease: A Critical Analysis Kadioglu, Ates et al. European Urology , Volume 50 , Issue 2 , 235 - 248
19. 16. Nehra, Ajay et al. "Peyronie's Disease: AUA Guideline" *Journal of urology* vol. 194,3 (2015): 745-53
20. National Institute for Health and Care Excellence.:  
<https://www.nice.org.uk/Media/Default/About/what-wedo/NICE-guidance/NICE-technology-appraisals/Block-scoping-reports/Block-scoping-reports-noCIC.pdf>

**Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. Individual cases will be reviewed as per the CCG policy.**

<b>Approved by (committee):</b>	Health and Care Commissioning Committee
<b>Date approved:</b>	March 2019
<b>Produced by:</b>	Clinical Commissioner
<b>Updated by:</b>	
<b>Review date:</b>	March 2021